FDA Experience with Medical Countermeasures under the Animal Rule
The Food and Drug Administration issued a final rule in May 2002 to permit the Agency to approve drugs or license biological products on the basis of animal efficacy studies for use in ameliorating or preventing serious or life-threatening conditions caused by exposure to lethal or permanently disab...
Main Author: | Paul Aebersold |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Advances in Preventive Medicine |
Online Access: | http://dx.doi.org/10.1155/2012/507571 |
Similar Items
-
Rabbitpox in New Zealand White Rabbits: A Therapeutic Model for Evaluation of Poxvirus Medical Countermeasures Under the FDA Animal Rule
by: Mark R. Perry, et al.
Published: (2018-10-01) -
Dose Selection in a Pandemic: A Framework Informed by the FDA Animal Rule
by: Kunyi Wu, et al.
Published: (2021-01-01) -
Understanding the new FDA pregnancy and lactation labeling rules
by: Collin M. Blattner, D.O.
Published: (2016-03-01) -
Development and Characterization of Ectromelia Virus-Moscow in the BALB/c Mouse Model for Smallpox Therapeutic and Prophylaxis Drug Efficacy Testing Under the FDA Animal Rule
by: Huettner, Lauren E.
Published: (2014) -
Additively manufactured medical products – the FDA perspective
by: Matthew Di Prima, et al.
Published: (2016-12-01)